Read Antitrust & Trade Regulation updates, alerts, news, and legal analysis from leading lawyers and law firms:
Too Big To Fail in the Dodd-Frank Era
Failed Unpaid Intern Class Action Hints at Impact of Comcast v. Behrend
License to travel: how regulation is benefiting business abroad
S&C's Cohen: Brown-Vitter Punishes Banks For Being Big
Tips for Mobile App Privacy Compliance
China's Export Policy Changes After U.S. Antitrust Case
Could A US-EU Free Trade Deal Harm The WTO?
$300 Million Dairy Settlement Will Bring Reform, Lawyer Says
Aquila: M&A Looking Up in 2013; "The Negatives Are Built In"
Suspicious Activity Reporting (SAR) under the Bank Secrecy Act and Anti-Money Laundering: What You Need to Know About the Safe Harbor and Limitations to Immunity
Martin Hahn on Food Labeling Lawsuits
What Every Exporter Needs to Know
Cross-Border M&A: Opportunities and Dealbreakers in Europe
Mike Koehler on Foreign Corrupt Practices Act Reform
Edelman 5 Step Process for Evaluation of Third Parties
Whalen: Too Much Regulation Caused JP Morgan $2 Billion Loss
Wal-Mart Bribery Allegations: Initial Impressions
Reverse-payment settlements between brand name and generic drug companies have remained a staple hot-button issue in the antitrust community for more than a decade. In some antitrust circles, simply mentioning the term...more
Par PharmaceuticalPar/Paddock, one of the generic drug company defendants in FTC v. Actavis Inc. et al. (the "reverse payment" ANDA settlement case now before the Supreme Court) filed its reponsive brief last week. In it,...more
Quadro macrofinanziario Analisi della normativa e dell'impianto regolatorio Proposte di riforma Aggiornato a Dicembre 2012...more
Skadden recently welcomed Sharis A. Pozen, former Acting Assistant Attorney General of the Antitrust Division of the U.S. Department of Justice, as a new partner in the firm’s Washington, D.C. office. Sharis discusses her DOJ...more
Law360, New York (August 24, 2012, 12:57 PM ET) -- Life sciences companies breathed a sigh of relief when the U.S. Supreme Court largely upheld the Patient Protection and Affordable Care Act (PPACA). After all, the PPACA will...more
The District of Delaware recently denied a motion to dismiss an antitrust counterclaim in a patent infringement action in the wake of defendant Mylan, Inc. ("Mylan") having filed an Abbreviated New Drug Application ("ANDA")...more
On July 6, 2011 the European Commission (Commission) published the results of its second monitoring exercise of patent settlements in the pharmaceutical sector (Second Monitoring Report). The Commission notes “with...more
Medical device cases are being filed with increasing frequency at the U.S. International Trade Commission (ITC) to combat infringing imports. In particular, owners of intellectual property rights on medical devices regularly...more
Fabio Pammolli e Nicola C. Salerno descrivono una proposta di rinnovamento complessivo della governance della spesa farmaceutica pubblica, con riferimento sia alla fascia "A" che alla fascia "H". I punti principali della...more
2 July 2010 – The U.S. House of Representatives has passed a measure banning patent settlements struck between brand-name and generic pharmaceutical companies to delay the release of generic drugs. The goal? To shave nearly...more
On 30 November 2010, European Commission officials carried out unannounced inspections at the premises of a number of pharmaceutical companies in several Member States. Reason was the Commission's suspicion that they may have...more
On January 13, 2010, the Federal Trade Commission released a study critical of “pay-for-delay” patent litigation settlements by which brand-name drug companies pay generic competitors to keep generic drugs off the market. The...more
In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe. Specifically, patent litigation settlements in which a brand pharmaceutical manufacturer makes a...more
We reported recently that the issue of reverse settlement payments to generic drug manufacturers was continuing to heat up this summer. FTC Chairman Jon Leibowitz’s recent comments on the issue further support this forecast....more
In early 2009, the Federal Trade Commission (‘‘FTC’’) launched its latest challenge to reverse payment settlements in the pharmaceutical industry, FTC v. Watson Pharmaceuticals (‘‘Watson’’).1 In a press release accompanying...more
On April 24, 2009, a group of professors of law, economics and business, together with the American Antitrust Institute, the Public Patent Foundation, and AARP (collectively "amici") filed an amicus brief urging the Supreme...more
On November 28, 2008, the European Commission published its preliminary report and findings in connection with the sector inquiry it launched late last year on competition in the pharmaceutical sector. The Commission...more
IN THIS ISSUE: *FTC Study: Spending on Kid Marketing Much Lower Than Thought *Court Strikes Down Ban on Ads for Alcohol *Good-bye Scrabulous, Hello Wordscraper *COPA Struck Down Yet Again *Supermarkets Squabble Over...more
IN THIS ISSUE: *New York Orders Chain Restaurants to Post Calories *ICANN to Clamp Down on Domain Name Abuse *FTC Fines Internet Ad Company $200,000 *FTC Goes After Alleged MySpace Hijackers *It's Official:...more
On January 16, 2008, the European Commission launched a sector inquiry into the pharmaceuticals industry by carrying out a series of unannounced inspections of innovative and generic pharmaceutical companies. The targeted...more
IN THIS ISSUE: *HIGHLIGHT ..U.S. Supreme Court Addresses Manufacturer Price Discrimination *RECENT DEVELOPMENTS ..Joint Venture Pricing Scrutinized ..Supreme Court Rules on Patent Tying ..Drug Companies Sued Over...more
JD Supra gets your content noticed, increases your visibility and makes your marketing efforts hassle free...
Learn More or Schedule a demo
